Literature DB >> 17320458

Fatality due to the use of a designer drug MDMA (Ecstasy).

Małgorzata Kłys1, Sebastian Rojek, Krzysztof Woźniak, Ewa Rzepecka-Woźniak.   

Abstract

Drugs of abuse belonging to the amphetamine derivatives, which are often taken by adolescents and young adults, pose a serious risk associated with uncontrolled ingestion that sometimes leads to fatal outcomes. The number of deaths, however, related to Ecstasy is small when compared to the frequency of its use. The report presents a fatal poisoning with MDMA--Ecstasy of a 22-year-old male with a documented history of drug abuse. The observations of witnesses to the event made within the period between the exposition and fatal outcome may document the characteristic behavior of a person in the course of progressive poisoning. Toxicological investigations of the autopsy specimens carried out by means of liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry (LC-APCI-MS-MS) demonstrated the presence of MDMA and its metabolite MDA in the blood of the victim, and the concentration level justified the fatal outcome (MDMA--1.42mg/L, MDA--0.17 mg/L), while the detection of high MDMA levels in a 6-cm long strand of hair separated into three segments (11.64 ng/mg in S1; 8.74 ng/mg in the S2; 15.51 ng/mg in the S3) confirmed the history of drug abuse. The report describing the results of macro and microscopic examinations aiming at assessing internal organ damage suggested a mild hepatic damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320458     DOI: 10.1016/j.legalmed.2006.12.004

Source DB:  PubMed          Journal:  Leg Med (Tokyo)        ISSN: 1344-6223            Impact factor:   1.376


  1 in total

1.  Determination of the role of calcium on instability of neurotoxic metabolite of ecstasy by HPTLC-mass.

Authors:  Bardia Jamali; Yalda Hosseinzadeh Ardakani; Mohammad-Reza Rouini; Alireza Foroumadi; Salimeh Amidi; Vahid Hossein Zadeh Aghdam; Farzad Kobarfard
Journal:  Daru       Date:  2013-01-17       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.